Oruka Therapeutics, Inc.
ORKA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $325,546 | $294,084 | $409,824 | $358,720 |
| - Cash | $61,575 | $37,431 | $42,445 | $53,359 |
| + Debt | $968 | $280 | $383 | $483 |
| Enterprise Value | $264,939 | $256,933 | $367,762 | $305,844 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$27 | -$111 | -$114 | -$91 |
| % Margin | – | – | – | – |
| EBITDA | -$82,229 | -$5,228 | -$9,812 | -$19,231 |
| % Margin | – | – | – | – |
| Net Income | -$83,724 | -$5,339 | -$9,926 | -$19,322 |
| % Margin | – | – | – | – |
| EPS Diluted | -4.99 | -4.44 | -8.27 | -16.68 |
| % Growth | -12.4% | 46.3% | 50.4% | – |
| Operating Cash Flow | -$57,837 | – | -$10,912 | -$18,762 |
| Capital Expenditures | -$189 | – | -$2 | -$43 |
| Free Cash Flow | -$58,026 | – | -$10,914 | -$18,805 |